Clene Inc.
CLNN
Price:
$5.02
Market Cap:
$32.48M
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multip...[Read more]
Industry
Biotechnology
IPO Date
2018-10-18
Stock Exchange
NASDAQ
Ticker
CLNN
The ROE as of September 2024 (TTM) for Clene Inc. (CLNN) is -315.97%
According to Clene Inc.’s latest financial reports and current stock price. The company's current ROE is -315.97%. This represents a change of -226.50% compared to the average of 249.78% of the last 4 quarters.
Clene Inc. (CLNN) Historical ROE (quarterly & annually)
How has CLNN ROE performed in the past?
The mean historical ROE of Clene Inc. over the last ten years is -936.24%. The current -315.97% ROE has changed -66.25% with respect to the historical average. Over the past ten years (40 quarters), CLNN's ROE was at its highest in in the June 2024 quarter at 1.35%. The ROE was at its lowest in in the March 2022 quarter at -698.17%.
Average
-936.24%
Median
-77.32%
Minimum
-5653.08%
Maximum
24.01%
Clene Inc. (CLNN) ROE by Quarter and Year
Discovering the peaks and valleys of Clene Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 510.46%
Maximum Annual ROE = 24.01%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -5653.08%
| Year | ROE | Change |
|---|---|---|
| 2023 | -369.71% | -21.67% |
| 2022 | -472.01% | 510.46% |
| 2021 | -77.32% | -98.63% |
| 2020 | -5653.08% | -23648.36% |
| 2019 | 24.01% | -532.84% |
| 2018 | -5.55% | -Infinity% |
Clene Inc. (CLNN) Average ROE
How has CLNN ROE performed in the past?
The current ROE of Clene Inc. (CLNN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-306.35%
5-year avg
-1309.62%
10-year avg
-936.24%
Clene Inc. (CLNN) ROE vs. Peers
How is CLNN’s ROE compared to its peers?
Clene Inc.’s ROE is less than MediciNova, Inc. (0%), greater than Eliem Therapeutics, Inc. (-13.37%), greater than Molecular Partners AG (-47.03%), greater than Champions Oncology, Inc. (-33.08%), less than Cyteir Therapeutics, Inc. (323.52%), greater than Century Therapeutics, Inc. (-23.13%), greater than Kezar Life Sciences, Inc. (-65.37%), greater than Mineralys Therapeutics, Inc. (-54.50%), greater than Nkarta, Inc. (-42.61%), greater than NGM Biopharmaceuticals, Inc. (-28.83%), greater than Ikena Oncology, Inc. (-76.46%), greater than Foghorn Therapeutics Inc. (-42.81%), less than Werewolf Therapeutics, Inc. (140.34%), greater than Immunome, Inc. (-48.25%), greater than Sensei Biotherapeutics, Inc. (-157.86%), greater than NextCure, Inc. (-48.14%), greater than Nuvation Bio Inc. (-57.63%), greater than Graphite Bio, Inc. (-98.79%), greater than Merrimack Pharmaceuticals, Inc. (-57.96%), greater than null (-35.28%),
| Company | ROE | Market cap |
|---|---|---|
| 0% | $76.02M | |
| -13.37% | $535.14M | |
| -47.03% | $160.66M | |
| -33.08% | $58.18M | |
| 323.52% | $108.71M | |
| -23.13% | $139.78M | |
| -65.37% | $42.06M | |
| -54.50% | $581.30M | |
| -42.61% | $371.84M | |
| -28.83% | $128.53M | |
| -76.46% | $80.11M | |
| -42.81% | $528.94M | |
| 140.34% | $97.02M | |
| -48.25% | $930.84M | |
| -157.86% | $12.22M | |
| -48.14% | $39.17M | |
| -57.63% | $719.91M | |
| -98.79% | $185.19M | |
| -57.96% | $223.97M | |
| -35.28% | $0 |
Build a custom stock screener for Clene Inc. (CLNN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Clene Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Clene Inc. (CLNN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Clene Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Clene Inc.'s ROE?
How is the ROE calculated for Clene Inc. (CLNN)?
What is the highest ROE for Clene Inc. (CLNN)?
What is the 3-year average ROE for Clene Inc. (CLNN)?
What is the 5-year average ROE for Clene Inc. (CLNN)?
How does the current ROE for Clene Inc. (CLNN) compare to its historical average?